Virax Biolabs Group (VRAX) Competitors

$0.12 -0.01 (-7.10%)

Closing price 04:00 PM Eastern

Extended Trading

$0.12 +0.00 (+1.89%)

As of 07:49 PM Eastern

VRAX vs. ADIL, TRIB, SLXN, ORGS, and VCNX

Should you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Adial Pharmaceuticals (ADIL), Trinity Biotech (TRIB), Silexion Therapeutics (SLXN), Orgenesis (ORGS), and Vaccinex (VCNX). These companies are all part of the "pharmaceutical products" industry.

How does Virax Biolabs Group compare to Adial Pharmaceuticals?

Adial Pharmaceuticals (NASDAQ:ADIL) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

: Adial Pharmaceuticals currently has a consensus price target of $22.75, indicating a potential upside of 1,321.88%. Virax Biolabs Group has a consensus price target of $1.00, indicating a potential upside of 721.69%. Given Adial Pharmaceuticals' higher possible upside, equities research analysts clearly believe Adial Pharmaceuticals is more favorable than Virax Biolabs Group.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adial Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Virax Biolabs Group
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Virax Biolabs Group's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Adial Pharmaceuticals N/A -182.34% -141.27%
Virax Biolabs Group N/A N/A N/A
: In the previous week, Adial Pharmaceuticals had 1 more articles in the media than Virax Biolabs Group. MarketBeat recorded 1 mentions for Adial Pharmaceuticals and 0 mentions for Virax Biolabs Group. Adial Pharmaceuticals' average media sentiment score of 0.00 equaled Virax Biolabs Group'saverage media sentiment score.
Company Overall Sentiment
Adial Pharmaceuticals Neutral
Virax Biolabs Group Neutral
: 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 1.9% of Adial Pharmaceuticals shares are owned by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Virax Biolabs Group has higher revenue and earnings than Adial Pharmaceuticals.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Adial Pharmaceuticals N/A N/A -$7.98M -$18.75 N/A
Virax Biolabs Group $10K 52.82 -$6.06M N/A N/A
: Adial Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-182.34%	-141.27%
Virax Biolabs Group	N/A	N/A	N/A

Company	Overall Sentiment
Adial Pharmaceuticals	Neutral
Virax Biolabs Group	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$18.75	N/A
Virax Biolabs Group	$10K	52.82	-$6.06M	N/A	N/A

Summary

Virax Biolabs Group beats Adial Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Virax Biolabs Group compare to Trinity Biotech?

Virax Biolabs Group (NASDAQ:VRAX) and Trinity Biotech (NASDAQ:TRIB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

: Virax Biolabs Group presently has a consensus price target of $1.00, indicating a potential upside of 721.69%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, research analysts clearly believe Virax Biolabs Group is more favorable than Trinity Biotech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virax Biolabs Group
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Trinity Biotech
1 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.50
: Virax Biolabs Group has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%.
Company Net Margins Return on Equity Return on Assets
Virax Biolabs Group N/A N/A N/A
Trinity Biotech -85.36% N/A -36.62%
: In the previous week, Trinity Biotech had 3 more articles in the media than Virax Biolabs Group. MarketBeat recorded 3 mentions for Trinity Biotech and 0 mentions for Virax Biolabs Group. Trinity Biotech's average media sentiment score of 0.67 beat Virax Biolabs Group's score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the news media.
Company Overall Sentiment
Virax Biolabs Group Neutral
Trinity Biotech Positive
: 8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by company insiders. Comparatively, 8.2% of Trinity Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Virax Biolabs Group has higher earnings, but lower revenue than Trinity Biotech.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Virax Biolabs Group $10K 52.82 -$6.06M N/A N/A
Trinity Biotech $43.78M 0.05 -$37.38M -$9.40 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Trinity Biotech	-85.36%	N/A	-36.62%

Company	Overall Sentiment
Virax Biolabs Group	Neutral
Trinity Biotech	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	52.82	-$6.06M	N/A	N/A
Trinity Biotech	$43.78M	0.05	-$37.38M	-$9.40	N/A

Summary

Virax Biolabs Group beats Trinity Biotech on 8 of the 12 factors compared between the two stocks.

How does Virax Biolabs Group compare to Silexion Therapeutics?

Virax Biolabs Group (NASDAQ:VRAX) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

: 8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 11.0% of Silexion Therapeutics shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by company insiders. Comparatively, 5.0% of Silexion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Virax Biolabs Group presently has a consensus price target of $1.00, indicating a potential upside of 721.69%. Given Virax Biolabs Group's higher possible upside, research analysts clearly believe Virax Biolabs Group is more favorable than Silexion Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virax Biolabs Group
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Silexion Therapeutics
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: In the previous week, Silexion Therapeutics had 1 more articles in the media than Virax Biolabs Group. MarketBeat recorded 1 mentions for Silexion Therapeutics and 0 mentions for Virax Biolabs Group. Silexion Therapeutics' average media sentiment score of 0.84 beat Virax Biolabs Group's score of 0.00 indicating that Silexion Therapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
Virax Biolabs Group Neutral
Silexion Therapeutics Positive
: Virax Biolabs Group's return on equity of 0.00% beat Silexion Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Virax Biolabs Group N/A N/A N/A
Silexion Therapeutics N/A -387.82% -144.68%
: Virax Biolabs Group has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Silexion Therapeutics has a beta of -0.29, suggesting that its share price is 129% less volatile than the S&P 500.
: Virax Biolabs Group has higher revenue and earnings than Silexion Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Virax Biolabs Group $10K 52.82 -$6.06M N/A N/A
Silexion Therapeutics N/A N/A -$11.91M -$11.10 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Overall Sentiment
Virax Biolabs Group	Neutral
Silexion Therapeutics	Positive

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Silexion Therapeutics	N/A	-387.82%	-144.68%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	52.82	-$6.06M	N/A	N/A
Silexion Therapeutics	N/A	N/A	-$11.91M	-$11.10	N/A

Summary

Virax Biolabs Group beats Silexion Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Virax Biolabs Group compare to Orgenesis?

Virax Biolabs Group (NASDAQ:VRAX) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

: 8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by company insiders. Comparatively, 5.7% of Orgenesis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: Virax Biolabs Group presently has a consensus price target of $1.00, indicating a potential upside of 721.69%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, equities analysts clearly believe Virax Biolabs Group is more favorable than Orgenesis.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virax Biolabs Group
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Orgenesis
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: In the previous week, Virax Biolabs Group's average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.
Company Overall Sentiment
Virax Biolabs Group Neutral
Orgenesis Neutral
: Virax Biolabs Group has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.
Company Net Margins Return on Equity Return on Assets
Virax Biolabs Group N/A N/A N/A
Orgenesis -3,827.81% N/A -130.18%
: Virax Biolabs Group has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Orgenesis has a beta of 3.07, suggesting that its stock price is 207% more volatile than the S&P 500.
: Virax Biolabs Group has higher earnings, but lower revenue than Orgenesis.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Virax Biolabs Group $10K 52.82 -$6.06M N/A N/A
Orgenesis $662K 4.65 -$55.36M -$11.51 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
Virax Biolabs Group	Neutral
Orgenesis	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Orgenesis	-3,827.81%	N/A	-130.18%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	52.82	-$6.06M	N/A	N/A
Orgenesis	$662K	4.65	-$55.36M	-$11.51	N/A

Summary

Virax Biolabs Group beats Orgenesis on 8 of the 11 factors compared between the two stocks.

How does Virax Biolabs Group compare to Vaccinex?

Virax Biolabs Group (NASDAQ:VRAX) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

: In the previous week, Vaccinex had 2 more articles in the media than Virax Biolabs Group. MarketBeat recorded 2 mentions for Vaccinex and 0 mentions for Virax Biolabs Group. Vaccinex's average media sentiment score of 0.72 beat Virax Biolabs Group's score of 0.00 indicating that Vaccinex is being referred to more favorably in the news media.
Company Overall Sentiment
Virax Biolabs Group Neutral
Vaccinex Positive
: Company Net Margins Return on Equity Return on Assets
Virax Biolabs Group N/A N/A N/A
Vaccinex N/A N/A -383.58%
: Virax Biolabs Group has higher earnings, but lower revenue than Vaccinex.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Virax Biolabs Group $10K 52.82 -$6.06M N/A N/A
Vaccinex $388K 7.04 -$20.25M -$48.27 N/A
: 8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by company insiders. Comparatively, 51.5% of Vaccinex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: Virax Biolabs Group presently has a consensus price target of $1.00, indicating a potential upside of 721.69%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, equities analysts clearly believe Virax Biolabs Group is more favorable than Vaccinex.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virax Biolabs Group
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Vaccinex
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Virax Biolabs Group has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.

Company	Overall Sentiment
Virax Biolabs Group	Neutral
Vaccinex	Positive

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Vaccinex	N/A	N/A	-383.58%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	52.82	-$6.06M	N/A	N/A
Vaccinex	$388K	7.04	-$20.25M	-$48.27	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Virax Biolabs Group and Vaccinex tied by winning 6 of the 12 factors compared between the two stocks.

Get Virax Biolabs Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRAX vs. The Competition

Export

Metric	Virax Biolabs Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$570K	$3.40B	$6.25B	$11.77B
Dividend Yield	N/A	2.23%	2.74%	5.26%
P/E Ratio	N/A	22.62	24.91	23.23
Price / Sales	52.82	280.78	504.56	75.49
Price / Cash	N/A	125.06	43.30	53.90
Price / Book	0.10	7.05	9.67	6.69
Net Income	-$6.06M	$23.62M	$3.55B	$332.64M
7 Day Performance	-9.04%	3.67%	1.70%	2.01%
1 Month Performance	-30.06%	7.17%	5.62%	9.19%
1 Year Performance	-88.01%	67.04%	34.42%	39.59%

Virax Biolabs Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRAX Virax Biolabs Group	1.7693 of 5 stars	$0.12 -7.1%	$1.00 +721.7%	N/A	$570K	$10K	N/A	5	Gap Down
ADIL Adial Pharmaceuticals	2.1069 of 5 stars	$1.55 -0.6%	$22.75 +1,367.7%	N/A	$2.21M	N/A	N/A	20
TRIB Trinity Biotech	0.3539 of 5 stars	$0.60 -2.1%	N/A	N/A	$2.15M	$61.56M	N/A	480
SLXN Silexion Therapeutics	1.1701 of 5 stars	$0.63 -0.9%	N/A	N/A	$2.10M	N/A	N/A	N/A	Positive News Upcoming Earnings High Trading Volume
ORGS Orgenesis	N/A	$0.40 -44.4%	N/A	N/A	$2.07M	$662K	N/A	150	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRAX) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virax Biolabs Group (VRAX) Competitors

VRAX vs. ADIL, TRIB, SLXN, ORGS, and VCNX

How does Virax Biolabs Group compare to Adial Pharmaceuticals?

Summary

How does Virax Biolabs Group compare to Trinity Biotech?

Summary

How does Virax Biolabs Group compare to Silexion Therapeutics?

Summary

How does Virax Biolabs Group compare to Orgenesis?

Summary

How does Virax Biolabs Group compare to Vaccinex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virax Biolabs Group (VRAX) Competitors

VRAX vs. ADIL, TRIB, SLXN, ORGS, and VCNX

How does Virax Biolabs Group compare to Adial Pharmaceuticals?

Summary

How does Virax Biolabs Group compare to Trinity Biotech?

Summary

How does Virax Biolabs Group compare to Silexion Therapeutics?

Summary

How does Virax Biolabs Group compare to Orgenesis?

Summary

How does Virax Biolabs Group compare to Vaccinex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools